Roivant Sciences (Nasdaq: ROIV) shows $3.9B cash and wider quarterly loss
Rhea-AI Filing Summary
Roivant Sciences Ltd. reported results for the three months ended June 30, 2026, with revenue of $1.4 million and a net loss of $290.6 million, compared with a $273.9 million net loss a year earlier. R&D expenses rose to $202.0 million and G&A to $165.5 million, driven in part by bonuses linked to the Moderna settlement. Non-GAAP net loss was $243.7 million, up from $170.1 million.
The company reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, excluding the $950 million payment Genevant and Arbutus received from Moderna in July under a $2.25 billion patent settlement, with an additional $1.3 billion contingent on a favorable Section 1498 appeal. Roivant repurchased 7.3 million common shares for approximately $208.7 million, and states this liquidity supports cash runway into profitability.
Operationally, Roivant is preparing for the potential U.S. launch of brepocitinib in dermatomyositis by the end of September 2026, has initiated a Phase 3 trial in cutaneous sarcoidosis, and continues late-stage development in non-infectious uveitis and lichen planopilaris. IMVT-1402 and mosliciguat programs remain on track, with multiple topline data readouts expected from 2026 through 2028, while Genevant pursues additional lipid nanoparticle patent actions against Pfizer and BioNTech.
Positive
- Strong liquidity bolstered by settlement: Consolidated cash, cash equivalents, restricted cash and marketable securities totaled $3.9 billion as of June 30, 2026, excluding the $950 million payment under the $2.25 billion Moderna patent settlement, supporting cash runway into profitability.
- Large capital return via buybacks: For the three months ended June 30, 2026, Roivant repurchased 7.3 million common shares for an aggregate repurchase price of approximately $208.7 million, signaling substantial capital deployment to share repurchases.
Negative
- Losses widened despite modest revenue: Non-GAAP net loss increased to $243.7 million for the quarter from $170.1 million a year earlier, as R&D rose to $202.0 million and G&A to $165.5 million, keeping the business significantly loss-making.
- Operating expense growth remains steep: Research and development expenses grew by $49.1 million year over year to $202.0 million, and general and administrative expenses rose by $31.5 million to $165.5 million, increasing the company’s cost base ahead of major product launches.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash, cash equivalents, restricted cash and marketable securities: $3.9 billion
Initial Moderna settlement payment to Genevant and Arbutus: $950 million
Net loss: $290.6 million
+5 more
8 metrics
Cash, cash equivalents, restricted cash and marketable securities
$3.9 billion
Consolidated balance as of June 30, 2026, excluding Moderna payment received in July
Initial Moderna settlement payment to Genevant and Arbutus
$950 million
Payment received in July 2026 under a $2.25 billion global patent settlement
Net loss
$290.6 million
Three months ended June 30, 2026, compared with $273.9 million in prior-year quarter
Non-GAAP net loss
$243.7 million
Three months ended June 30, 2026, versus $170.1 million for the three months ended June 30, 2025
Research and development expenses
$202.0 million
Quarter ended June 30, 2026, up from $152.9 million a year earlier
General and administrative expenses
$165.5 million
Quarter ended June 30, 2026, compared with $134.0 million for the prior-year quarter
Share repurchases
7.3 million shares for approximately $208.7 million
Common shares repurchased during the three months ended June 30, 2026
Total assets
$5,306,493 thousand
Total assets as of June 30, 2026, per selected balance sheet data (in thousands)
Key Terms
Breakthrough Therapy Designation, cutaneous sarcoidosis, non-infectious uveitis, FcRn, +2 more
6 terms
Breakthrough Therapy Designation regulatory
"which led to FDA Breakthrough Therapy Designation."
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
cutaneous sarcoidosis medical
"Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS)."
Cutaneous sarcoidosis is the form of sarcoidosis that affects the skin, where the body's immune response produces small, firm lumps or patches that may look like rashes or raised bumps. It matters to investors in healthcare and pharmaceuticals because visible skin involvement can indicate disease severity, change who qualifies for clinical trials, influence regulatory labeling and reimbursement, and affect demand and long‑term treatment costs—like a visible warning light that alters clinical and market decisions.
non-infectious uveitis medical
"Phase 3 study in non-infectious uveitis (NIU) expected"
Non-infectious uveitis is inflammation of the eye’s middle layer (uvea) caused by the body's immune response rather than by bacteria, viruses, or fungi — like an internal allergy or auto-attack on eye tissue. It matters to investors because it can lead to chronic vision loss, creating demand for long-term treatments, influencing clinical trial design, regulatory approvals, and recurring-revenue opportunities for therapies that reduce inflammation and preserve vision.
FcRn medical
"IMVT-1402, a fully human monoclonal antibody targeting FcRn"
The neonatal Fc receptor (FCRN or FcRn) is a protein that controls how long antibodies and the blood protein albumin stay in circulation by protecting them from being broken down. For investors, therapies that block or harness FcRn can change a drug’s dosing, effectiveness and market appeal—either by lengthening beneficial antibodies for longer-lasting treatments or by reducing harmful antibodies in autoimmune disease—so progress in FcRn-targeted programs can materially affect a biotech’s commercial value.
Section 1498 regulatory
"contingent on favorable resolution of Moderna’s Section 1498 appeal"
Section 1498 is a U.S. federal law that lets the government, or parties it authorizes, use or make a patented invention without the patent owner’s prior permission, while requiring the government to pay monetary compensation through a special claims process. For investors, it matters because it can remove or shorten a company’s exclusive control over a product—for example allowing broader manufacturing or sales—potentially reducing future revenue, altering competitive dynamics, and affecting valuation; think of it as the government borrowing a company’s tool and promising to settle the bill later.
lipid nanoparticle technology technical
"seeking to enforce patents protecting their innovative lipid nanoparticle technology."
Earnings Snapshot
Revenue: $1,442 thousand
three months ended June 30, 2026
Revenue
$1,442 thousand
Decreased from $2,170 thousand for the three months ended June 30, 2025
Net loss
$290.6 million
Increased from $273.9 million net loss for the three months ended June 30, 2025
Non-GAAP net loss
$243.7 million
Increased from $170.1 million non-GAAP net loss for the three months ended June 30, 2025
Research and development expenses
$202.0 million
Up from $152.9 million for the three months ended June 30, 2025
General and administrative expenses
$165.5 million
Up from $134.0 million for the three months ended June 30, 2025
Cash, cash equivalents, restricted cash and marketable securities
$3.9 billion
Reported as of June 30, 2026, excluding the $950 million Moderna payment received in July 2026
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Roivant Sciences (ROIV) key financial results for the quarter ended June 30, 2026?
Roivant reported revenue of $1.4 million and a net loss of $290.6 million for the three months ended June 30, 2026. Non-GAAP net loss was $243.7 million, reflecting higher R&D and G&A expenses compared with the prior-year quarter.
How much cash and liquidity does Roivant Sciences (ROIV) have as of June 30, 2026?
As of June 30, 2026, Roivant had $3.9 billion in consolidated cash, cash equivalents, restricted cash and marketable securities. This figure excludes the $950 million payment Genevant and Arbutus received from Moderna in July under a $2.25 billion settlement.
What is the status of brepocitinib in Roivant Sciences (ROIV) pipeline?
Roivant reports that commercial preparations for brepocitinib in dermatomyositis are progressing well and on track for launch by the end of September 2026. A Phase 3 trial in cutaneous sarcoidosis has begun, with topline data expected in calendar year 2028.
What does the Moderna settlement mean for Roivant Sciences (ROIV) through Genevant?
Genevant and Arbutus received $950 million from Moderna in July 2026 as the initial payment under a $2.25 billion global patent settlement. An additional $1.3 billion payment is contingent on a favorable resolution of Moderna’s Section 1498 appeal.
What are upcoming clinical milestones for Roivant Sciences (ROIV) programs IMVT-1402 and mosliciguat?
Roivant expects topline proof-of-concept data for IMVT-1402 in CLE and an update on its D2T RA program in the second half of 2026, with additional registrational data through 2028. For mosliciguat, Phase 2 PH-ILD topline data are expected in the second half of 2026.
How did Roivant Sciences (ROIV) operating expenses change year over year?
For the quarter ended June 30, 2026, R&D expenses rose to $202.0 million from $152.9 million, and G&A expenses increased to $165.5 million from $134.0 million. Increases were driven by program-specific costs and personnel-related expenses, including bonuses tied to the Moderna settlement.